<DOC>
	<DOC>NCT01756612</DOC>
	<brief_summary>This prospective, multicenter, observational study will evaluate the impact of comorbidity factors on the hemoglobin level in participants with chronic kidney disease who are not on dialysis and initiated on treatment with methoxy polyethylene glycol-epoetin beta (Mircera). Data will be collected for 9 months after initiation of methoxy polyethylene glycol-epoetin beta treatment.</brief_summary>
	<brief_title>A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants with chronic kidney disease not on dialysis Treatmentna√Øve for erythropoiesisstimulating agents (ESAs), not having received ESAs in the 6 months prior to inclusion in this study Hemoglobin level less then (&lt;)10 grams per deciliter (g/dL) at inclusion Participants for whom the treating physician has decided to initiate treatment with methoxy polyethylene glycolepoetin beta for medical reasons prior to study start Functional renal transplant Current participation in a clinical trial in anemia due to chronic kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>